Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd maintains a strong liquidity position, with a current ratio of 2.35 and cash and equivalents amounting to 2.94 billion CNY. The company's debt-to-equity ratio is 0.0, indicating no long-term debt obligations, and its free cash flow of 1.23 billion CNY supports operational flexibility. The company's profitability is robust, with a return on equity of 28.42% and a return on assets of 20.7%. These metrics exceed the typical thresholds for pharmaceutical firms, suggesting efficient use of equity and assets to generate returns. Geographically, the company's revenue is concentrated in China, as disclosed in its segments. No international revenue breakdown is available, but the company's operations are primarily domestic. This concentration may expose the company to regulatory and economic risks specific to the Chinese market. The company's growth trajectory is positive, with a net income of 2.23 billion CNY and an operating income of 2.51 billion CNY. While no specific growth rate is provided, the company's strong cash flow and profitability suggest a stable and potentially growing business. The company's risk profile is low, with no immediate liquidity or dilution flags detected. The absence of long-term debt and the presence of substantial cash reserves reduce financial risk. Additionally, the company's low dilution potential and stable share count suggest a conservative capital structure. Recent events, including analyst estimates and ESG scores, indicate a generally positive outlook. The company's ESG score of 66.23 and a governance score of 87.19 reflect a commitment to responsible business practices. However, the social pillar score of 48.07 suggests areas for improvement in social responsibility.